Related Experiment Video
Updated: May 1, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses
Liddy M Chen1, Joseph G Ibrahim, Haitao Chu
1a Global Research Operation, Biostatistics, PAREXEL International , Durham , North Carolina , USA.
Abstract:
It has been widely recognized that interim analyses of accumulating data in a clinical trial can inflate type I error. Different methods, from group sequential boundaries to flexible alpha spending functions, have been developed to control the overall type I error at prespecified level. These methods mainly apply to testing the same endpoint in multiple interim analyses. In this article, we consider a group sequential design with preplanned endpoint switching after unblinded interim analyses. We extend the alpha spending function method to group sequential stopping boundaries when the parameters can be different between interim, or between interim and final analyses.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence studies: Biowaivers
FDA Approved Drugs: Changes to Approved Drugs
Bioavailability Study Design: Healthy Subjects Versus Patients
Blinding
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
